Technical Analysis for NCNA - NuCana plc

Grade Last Price % Change Price Change
grade C 13.21 -0.83% -0.11
NCNA closed down 0.83 percent on Wednesday, January 17, 2018, on 43 percent of normal volume.
0 Watchers
Track This Stock
Watchlist Portfolio

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A Up Up
See historical NCNA trend table...

Date Alert Name Type % Chg
Jan 17 Slingshot Bullish Bullish Swing Setup 0.00%
Jan 17 Upper Bollinger Band Walk Strength 0.00%
Jan 17 Wide Bands Range Expansion 0.00%
Jan 16 Bearish Engulfing Bearish -0.83%
Jan 16 Stochastic Sell Signal Bearish -0.83%
Jan 16 Slingshot Bullish Bullish Swing Setup -0.83%
Jan 16 Wide Range Bar Range Expansion -0.83%
Jan 16 Upper Bollinger Band Walk Strength -0.83%
Jan 16 Outside Day Range Expansion -0.83%
Jan 16 Wide Bands Range Expansion -0.83%

Older signals for NCNA ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
NuCana PLC is a clinical-stage biopharmaceutical company. The Company is focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The Company utilizes its ProTide technology to develop medicines to overcome cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline of products includes Acelarin, NUC-3373 and NUC-7738. Acelarin is a nucleotide analog and is a ProTide transformation of gemcitabine for the treatment of cancer. The Company is evaluating Acelarin in four clinical trials across several solid tumor indications. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil for the treatment of a wide range of cancers. NUC-3373 is in a Phase I trial for the potential treatment of a wide range of solid tumor cancers. NUC-7738 is a ProTide transformation of cordycepin, a novel nucleoside analog.
Is NCNA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 0 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 19.95
52 Week Low 9.32
Average Volume 54,070
200-Day Moving Average 0.0
50-Day Moving Average 11.4406
20-Day Moving Average 11.4265
10-Day Moving Average 12.401
Average True Range 1.1107
ADX 20.46
+DI 25.26
-DI 21.34
Chandelier Exit (Long, 3 ATRs ) 11.4679
Chandelier Exit (Short, 3 ATRs ) 12.6521
Upper Bollinger Band 14.2528
Lower Bollinger Band 8.6002
Percent B (%b) 0.82
BandWidth 49.469216
MACD Line 0.5539
MACD Signal Line 0.1737
MACD Histogram 0.3802
Fundamentals Value
Market Cap 420.23 Million
Num Shares 31.8 Million
EPS -0.40
Price-to-Earnings (P/E) Ratio -33.03
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 16.51
Resistance 3 (R3) 16.34 15.08 15.96
Resistance 2 (R2) 15.08 14.24 15.16 15.78
Resistance 1 (R1) 14.14 13.72 14.61 14.31 15.59
Pivot Point 12.88 12.88 13.11 12.96 12.88
Support 1 (S1) 11.94 12.04 12.41 12.11 10.83
Support 2 (S2) 10.68 11.52 10.76 10.64
Support 3 (S3) 9.74 10.68 10.46
Support 4 (S4) 9.91